146 related articles for article (PubMed ID: 8041895)
1. Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada.
Hendry JH; Roberts SA; Slevin NJ; Keane TJ; Barton MB; Agren-Cronqvist A
Radiother Oncol; 1994 Apr; 31(1):14-22. PubMed ID: 8041895
[TBL] [Abstract][Full Text] [Related]
2. Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.
Roberts SA; Hendry JH
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1247-57. PubMed ID: 10613320
[TBL] [Abstract][Full Text] [Related]
3. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.
Slevin NJ; Hendry JH; Roberts SA; Agren-Cronqvist A
Radiother Oncol; 1992 Aug; 24(4):215-20. PubMed ID: 1410576
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of human squamous cell carcinoma of the larynx to fractionated radiotherapy.
Rezvani M; Fowler JF; Hopewell JW; Alcock CJ
Br J Radiol; 1993 Mar; 66(783):245-55. PubMed ID: 8472118
[TBL] [Abstract][Full Text] [Related]
5. Dose, time, and fraction size issues for late effects in head and neck cancers.
Taylor JM; Mendenhall WM; Lavey RS
Int J Radiat Oncol Biol Phys; 1992; 22(1):3-11. PubMed ID: 1727126
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules.
Garden AS; Morrison WH; Ang KK; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):493-502. PubMed ID: 7852111
[TBL] [Abstract][Full Text] [Related]
7. Tumour volume: implications in T2/T3 glottic/supraglottic squamous cell carcinoma.
Lo SM; Venkatesan V; Matthews TW; Rogers J
J Otolaryngol; 1998 Oct; 27(5):247-51. PubMed ID: 9800621
[TBL] [Abstract][Full Text] [Related]
8. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.
Ricciardelli EJ; Weymuller EA; Koh WJ; Austin-Seymour M; DeSautel MG; Laramore GE
Arch Otolaryngol Head Neck Surg; 1994 Jul; 120(7):737-42. PubMed ID: 8018326
[TBL] [Abstract][Full Text] [Related]
9. 331 cases of clinically node-negative supraglottic carcinoma of the larynx: a study of a modest size fixed field radiotherapy approach.
Sykes AJ; Slevin NJ; Gupta NK; Brewster AE
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1109-15. PubMed ID: 10725620
[TBL] [Abstract][Full Text] [Related]
10. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
[TBL] [Abstract][Full Text] [Related]
11. [Radiotherapy of carcinoma of the larynx--dose and function preservation].
Nakano M; Iida K; Sato S; Sakata S; Sueyama H
Gan No Rinsho; 1985 Sep; 31(12):1602-4. PubMed ID: 4079049
[TBL] [Abstract][Full Text] [Related]
12. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
Roberts SA; Hendry JH; Slevin NJ
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
[TBL] [Abstract][Full Text] [Related]
13. Radical radiotherapy for carcinoma of the larynx--Westmead Hospital experience.
Turner SL; Tiver KW
Australas Radiol; 1991 Aug; 35(3):242-7. PubMed ID: 1763987
[TBL] [Abstract][Full Text] [Related]
14. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer.
Barton MB; Keane TJ; Gadalla T; Maki E
Radiother Oncol; 1992 Mar; 23(3):137-43. PubMed ID: 1574592
[TBL] [Abstract][Full Text] [Related]
15. Regression after 50 Gy as a selection for therapy in advanced laryngeal cancer.
Terhaard CH; Wiggenraad RG; Hordijk GJ; Ravasz LA
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):591-7. PubMed ID: 3138211
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy of glottic carcinoma: Peter MacCallum Cancer Institute experience.
Guiney M; Smith J; Hughes P; Narayan K
Aust N Z J Surg; 1992 Aug; 62(8):622-7. PubMed ID: 1642583
[TBL] [Abstract][Full Text] [Related]
17. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx.
Overgaard J; Hjelm-Hansen M; Johansen LV; Andersen AP
Acta Oncol; 1988; 27(2):147-52. PubMed ID: 3390345
[TBL] [Abstract][Full Text] [Related]
18. Local control of T3 carcinomas after accelerated fractionation: a look at the "gap".
Wang CC; Efird J; Nakfoor B; Martins P
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):439-41. PubMed ID: 8655365
[TBL] [Abstract][Full Text] [Related]
19. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
Krstevska V; Crvenkova S
Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
[TBL] [Abstract][Full Text] [Related]
20. Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx.
Maciejewski B; Taylor JM; Withers HR
Radiother Oncol; 1986 Dec; 7(4):323-6. PubMed ID: 3809591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
